Frankfurt
26.06.26 | 15:25
2,760 Euro
-3,50 % -0,100
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INVENTIVA SA ADR Aktie jetzt für 0€ handeln | |||||
| 12.06. | INVENTIVA: Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing | 517 | GlobeNewswire (Europe) | Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2... ► Artikel lesen | |
| 12.06. | Inventiva S.A. - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 09.06. | INVENTIVA: Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents | 519 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 9,2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 09.06. | INVENTIVA: Statement of Total Voting Rights and Shares Forming The Company's Share Capital as of May 22, 2026 | 319 | GlobeNewswire (Europe) | Article R. 22-10-23 of the French Commercial Code
Market: Euronext Paris
ISIN code / Mnemo: FR0013233012 / IVA
Web site: www.inventivapharma.com
DateNumber of Shares OutstandingTotal... ► Artikel lesen | |
| 03.06. | Inventiva S.A. - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 02.06. | INVENTIVA: Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris | 287 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 02.06. | INVENTIVA: Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout | 541 | GlobeNewswire (Europe) | Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an additional... ► Artikel lesen | |
| 02.06. | INVENTIVA: Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris | 658 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), June 2, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 27.05. | Inventiva S.A reports Q1 results | 2 | Seeking Alpha | ||
| 26.05. | INVENTIVA: Inventiva Reports 2026 First Quarter Financial Information | 1.644 | GlobeNewswire (Europe) | Cash and cash equivalents at €75.0 million, and €121.5 million in short-term deposits2
Daix (France), New York City (New York, United States), May 26, 2026 - Inventiva (Euronext Paris and NASDAQ:... ► Artikel lesen | |
| 22.05. | Inventiva S.A. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 21.05. | INVENTIVA: Inventiva to Present at 2026 Jefferies Global Healthcare Conference | 394 | GlobeNewswire (Europe) | Daix (France), New York (United States), May 21, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 13.05. | INVENTIVA: Inventiva to Present Abstracts at the EASL Congress 2026 | 446 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), May 13, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on... ► Artikel lesen | |
| 01.05. | Inventiva appoints Axel-Sven Malkomes as Chief Financial Officer | 9 | PMLiVE | ||
| 22.04. | Inventiva announces CFO appointment | 2 | Seeking Alpha | ||
| 22.04. | Inventiva stärkt Führungsteam vor entscheidenden Studienergebnissen | 11 | Investing.com Deutsch | ||
| 22.04. | INVENTIVA: Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor | 615 | GlobeNewswire (Europe) | Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva's organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes... ► Artikel lesen | |
| 22.04. | Inventiva S.A. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 08.04. | INVENTIVA: Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F | 649 | GlobeNewswire (Europe) | Daix (France), New York City (New York, United States), April 8, 2026 - Inventiva (Euronext Paris and NASDAQ: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development... ► Artikel lesen | |
| 08.04. | Inventiva S.A. - 20-F, Annual and transition report of foreign private issuers | 4 | SEC Filings |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,456 | -1,68 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA | NASDAQ | TSX: ACB
Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth
Delivers Record Annual Adjusted EBITDA1 of $53.8 million... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 429,65 | -0,38 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| CRONOS GROUP | 2,440 | -1,37 % | Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders | TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June... ► Artikel lesen | |
| VIATRIS | 14,288 | -0,39 % | VTRS vs. DHR: Which Stock Is the Better Value Option? | ||
| EYEPOINT | 12,600 | +5,00 % | Mizuho reiterates EyePoint stock rating on competitor timeline shift | ||
| BAUSCH HEALTH | 4,288 | +2,24 % | Bausch Health Companies Inc.: Bausch Health Announces 2026 Annual Meeting of Shareholder Results | LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 79,80 | +0,08 % | Edwards Lifesciences stellt neue Studiendaten zu Herzklappentherapien vor | ||
| ORGANIGRAM GLOBAL | 0,870 | -4,29 % | Organigram Global Inc.: Organigram Closes Previously Announced Acquisition of Sanity Group, Private Placement Financing with BAT and ATB Senior Secured Credit Facilities | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram") and Sanity Group GmbH ("Sanity" or "Sanity Group") jointly announced the successful closing of Organigram's previously... ► Artikel lesen | |
| SNDL | 1,162 | -4,44 % | 1CM Inc.: 1CM Provides Update on Arrangement Agreement with SNDL | Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) ("1CM") announces that it does not expect the proposed sale of its Ontario retail locations to... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 3,304 | +0,36 % | Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy | ||
| HAPPY BELLY FOOD GROUP | 1,020 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Rosie's Burgers Secures Greater Montreal's First South Shore Real-Estate Location in Longueil's Greenfield Park, Quebec | Toronto, Ontario--(Newsfile Corp. - June 22, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 11,285 | -2,42 % | Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts | ||
| FILANA THERAPEUTICS | 1,028 | -2,10 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| CANTOURAGE GROUP | 6,160 | -1,60 % | EQS-DD: Cantourage Group SE: Monique Jaqqam, Anderes aus Aktie/Schuldtitel bez. FI Annahme der Gewährung von 25.000 Aktienoptionen (Bezugsrechten auf Aktien der Cantourage Group SE; ISIN: ... | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
05.06.2026 / 21:09... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 4,315 | +5,12 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen |
INVENTIVA SA ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -3,50 % bei einem Aktienkurs von 2,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INVENTIVA SA ADR finden Sie auf Wallstreet Online.